Quantcast

Industry news that matters to you.  Learn more

Roche, UCLA Announce Biomarker Research Collaboration

Reading time: 2 minutes

Roche said last week that it will provide UCLA scientists with a range of genomics tools as part of a research collaboration to study stem cells and cancer, and for the development of new predictive biomarkers for future therapeutics and diagnostics for a host of diseases.

Under the agreement, Roche will provide scientists at the Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research at UCLA and UCLA’s Jonsson Comprehensive Cancer Center with valuable technology directly from Roche’s research and development pipeline, including the latest generation microarray systems from Roche NimbleGen, high-throughput screening instruments, genetic expression profilers and exome sequencing technologies.

Robert Yates, Head of Roche Applied Science said:

Our focus is to provide the scientific community with cutting-edge genomic tools that can rapidly advance their research. This collaboration is an innovative approach to working closely with leading institutes, such as UCLA, at an early stage of research in the pursuit of new predictive biomarkers. By working together at an early stage, we can optimize the technologies and provide the necessary support to improve detection and analysis, and ultimately, the success rate of biomarker discovery.

The collaborative agreement allows UCLA and Roche scientists to work together with an initial focus on developing even more effective technologies for academic and commercial use. Future developments, based on these technologies, could lead to clinical trials of promising diagnostics and therapeutics. An advisory committee comprised of Roche and UCLA scientists will review and select project applications from UCLA researchers for studies that propose the best use of the technology and which are most likely to succeed.

Source: Roche